UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,932	05/05/2006	Yechezkel Barenholz	BARENHOLZ14	4072
	7590 08/18/200 D NEIMARK, P.L.L.C	EXAMINER		
624 NINTH STREET, NW			LE, EMILY M	
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			08/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## 10560932 BARENHOLZ ET AL. **Notice to Comply**

Application No.

ENTO FOR RATENT APPLICATIONS CONTAIL						
	EMILY M. LE	1648				
	Examiner	Art Unit				

Applicant(s)

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY						
For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software is Available At www.USPTO.gov						
For questions regarding compliance to these requirements, please contact:  For Rules Interpretation, call (571) 272-0731 or (571) 272-0951						
include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
its entry into the application.  A statement that the content of the paper and computer readable copies are the same and, where applicable,						
Applicant Must Provide:  ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing						
accompanied by a sequence identifier, SEQ ID NO:.						
Listing" as required by 37 C.F.R. 1.821(e).  7. Other: The specification contains nucleic acid sequence(s) that are encompassed by the sequence requirements. For example, lines 21-22, page 24 of the specification. The noted sequence(s) are not						
must be submitted as required by 37 C.F.R. 1.825(d).  6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence						
the attached copy of the marked -up "Raw Sequence Listing."  5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form						
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on						
	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by					
	s application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as					
1. This application clearly fails to comply with the requirement directed to the final rulemaking notice published at 55 FR 18 If the effective filing date is on or after July 1, 1998, see the (June 1, 1998) and 1211 OG 82 (June 23, 1998).	8230 (May 1, 1990), and 1114 OG 29 (May 15, 1990).					
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):						
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).						
	O MOID OLGOLINOL DIOCLOCOMIC					